Preliminary Exploration of Correlation between <i>p53</i> Gene Mutation and Epithelial Ovarian Cancer Pathogenesis Types_West China Medical Journal

Authors：

 DuanRuiqi ,  XiMingrong

Department of Gynaecology and Obstetrics, West China Second University Hospital, Sichuan University, Chengdu, Sichuan 610041, P. R. China;

Corresponding author：

XiMingrong, Email: qmrjzz@126.com

Keywords：

Epithelial ovarian cancer; Dualism; p53 mutation

DOI：

10.7507/1002-0179.201600378

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To explore the relationship between p53 mutation in 5-8 exons and type of epithelial ovarian cancer (EOC) pathogenesis of Han nationality women. Methods From August 2011 to December 2012, 45 patients with primary EOC (Han nationality women from Sichuan Province) diagnosed surgically and pathologically were selected. Using direct DNA sequencing, we analyzed the mutations of p53 in 5-8 exons of all cases, and the EOC patients were divided into two types according dualism and the pathogenesis results. The p53 mutation of the different types in EOC patients were analyzed. Results The frequency and efficiency of p53 mutation in type-ⅡEOC patients were significantly higher than that in typeⅠ(P < 0.01). And the codon 175 might be a mutational hotspot of type-ⅡEOC. The malignant degree and oviduct involved frequency of type-ⅡEOC were obviously higher than that of type-I EOC; p53 mutation frequency in high malignant patients increased significantly. Conclusions p53 mutation plays an important role in the development of type-ⅡEOC. The codon 175 might be a mutational hotspot of type-ⅡEOC.

Citation： DuanRuiqi, XiMingrong. Preliminary Exploration of Correlation between p53 Gene Mutation and Epithelial Ovarian Cancer Pathogenesis Types. West China Medical Journal, 2016, 31(8): 1389-1393. doi: 10.7507/1002-0179.201600378 Copy

1.	Salehi HS, Kumavor PD, Li H, et al. Design of optimal light delivery system for co-registered transvaginal ultrasound and photoacoustic imaging of ovarian tissue[J]. Photoacoustics, 2015, 3(3):114-122.
2.	Kreuzinger C, Gamperl M, Wolf A, et al. Molecular characterization of 7 new established cell lines from high grade serous ovarian cancer[J]. Cancer Lett, 2015, 362(2):218-228.
3.	Bankhead CR, Collins C, Stokes-Lampard H, et al. Identifying symptoms of ovarian cancer:a qualitative and quantitative study[J]. BJOG, 2008, 115(8):1008-1014.
4.	Rainczuk A, Rao JR, Gathercole JL, et al. Evidence for the antagonistic form of CXC-motif chemokine CXCL10 in serous epithelial ovarian tumours[J]. Int J Cancer, 2014, 134(3):530-541.
5.	Landen CN Jr, Birrer MJ, Sood AK. Early events in the pathogenesis of epithelial ovarian cancer[J]. J Clin Oncol, 2008, 26(6):995-1005.
6.	Kurman RJ, Shih IeM. The origin and pathogenesis of epithelial ovarian cancer:a proposed unifying theory[J]. Am J Surg Pathol, 2010, 34(3):433-443.
7.	Shih IeM, Kurman RJ. Ovarian tumorigenesis:a proposed model based on morphological and molecular genetic analysis[J]. Am J Pathol, 2004, 164(5):1511-1518.
8.	Sabbah M, Emami S, Redeuilh G, et al. Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers[J]. Drug Resist Updat, 2008, 11(4/5):123-151.
9.	Salvador S, Gilks B, Köbel M, et al. The fallopian tube:primary site of most pelvic high-grade serous carcinomas[J]. Int J Gynecol Cancer, 2009, 19(1):58-64.
10.	Phillips KA, Nichol K, Ozcelik H, et al. Frequency of p53 mutations in breast carcinomas from Ashkenazi Jewish carriers of BRCA1 mutations[J]. J Natl Cancer Inst, 1999, 91(5):469-473.
11.	Reedy MB, Hang T, Gallion H, et al. Antisense inhibition of BRCA1 expression and molecular analysis of hereditary tumors indicate that functional inactivation of the p53 DNA damage response pathway is required for BRCA-associated tumorigenesis[J]. Gynecol Oncol, 2001, 81(3):441-446.
12.	Wong KK, Izaguirre DI, Kwan SY, et al. Poor survival with wild-type Tp53 ovarian cancer?[J]. Gynecol Oncol, 2013, 130(3):565-569.
13.	Hammel P, Leroy-Viard K, Chaumette MT, et al. Correlations between p53-protein accumulation, serum antibodies and gene mutation in colorectal cancer[J]. Int J Cancer, 1999, 81(5):712-718.
14.	Gadducci A, Ferdeghini M, Buttitta F, et al. Assessment of the prognostic relevance of serum anti-p53 antibodies in epithelial ovarian cancer[J]. Gynecol Oncol, 1999, 72(1):76-81.
15.	Wong AS, Leung PC. Role of endocrine and growth factors on the ovarian surface epithelium[J]. J Obstet Gynaecol Res, 2007, 33(1):3-16.
16.	Callahan MJ, Crum CP, Medeiros F, et al. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction[J]. J Clin Oncol, 2007, 25(25):3985-3990.
17.	Kindelberger DW, Lee Y, Miron A, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma:evidence for a causal relationship[J]. Am J Surg Pathol, 2007, 31(2):161-169.
18.	Lee Y, Miron A, Drapkin R, et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube[J]. J Pathol, 2007, 211(1):26-35.
19.	Levanon K, Crum C, Drapkin R. New insights into the pathogenesis of serous ovarian cancer and its clinical impact[J]. J Clin Oncol, 2008, 26(32):5284-5293.
20.	Folkins AK, Jarboe EA, Roh MH, et al. Precursors to pelvic serous carcinoma and their clinical implications[J]. Gynecol Oncol, 2009, 113(3):391-396.

1. Salehi HS, Kumavor PD, Li H, et al. Design of optimal light delivery system for co-registered transvaginal ultrasound and photoacoustic imaging of ovarian tissue[J]. Photoacoustics, 2015, 3(3):114-122.
2. Kreuzinger C, Gamperl M, Wolf A, et al. Molecular characterization of 7 new established cell lines from high grade serous ovarian cancer[J]. Cancer Lett, 2015, 362(2):218-228.
3. Bankhead CR, Collins C, Stokes-Lampard H, et al. Identifying symptoms of ovarian cancer:a qualitative and quantitative study[J]. BJOG, 2008, 115(8):1008-1014.
4. Rainczuk A, Rao JR, Gathercole JL, et al. Evidence for the antagonistic form of CXC-motif chemokine CXCL10 in serous epithelial ovarian tumours[J]. Int J Cancer, 2014, 134(3):530-541.
5. Landen CN Jr, Birrer MJ, Sood AK. Early events in the pathogenesis of epithelial ovarian cancer[J]. J Clin Oncol, 2008, 26(6):995-1005.
6. Kurman RJ, Shih IeM. The origin and pathogenesis of epithelial ovarian cancer:a proposed unifying theory[J]. Am J Surg Pathol, 2010, 34(3):433-443.
7. Shih IeM, Kurman RJ. Ovarian tumorigenesis:a proposed model based on morphological and molecular genetic analysis[J]. Am J Pathol, 2004, 164(5):1511-1518.
8. Sabbah M, Emami S, Redeuilh G, et al. Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers[J]. Drug Resist Updat, 2008, 11(4/5):123-151.
9. Salvador S, Gilks B, Köbel M, et al. The fallopian tube:primary site of most pelvic high-grade serous carcinomas[J]. Int J Gynecol Cancer, 2009, 19(1):58-64.
10. Phillips KA, Nichol K, Ozcelik H, et al. Frequency of p53 mutations in breast carcinomas from Ashkenazi Jewish carriers of BRCA1 mutations[J]. J Natl Cancer Inst, 1999, 91(5):469-473.
11. Reedy MB, Hang T, Gallion H, et al. Antisense inhibition of BRCA1 expression and molecular analysis of hereditary tumors indicate that functional inactivation of the p53 DNA damage response pathway is required for BRCA-associated tumorigenesis[J]. Gynecol Oncol, 2001, 81(3):441-446.
12. Wong KK, Izaguirre DI, Kwan SY, et al. Poor survival with wild-type Tp53 ovarian cancer?[J]. Gynecol Oncol, 2013, 130(3):565-569.
13. Hammel P, Leroy-Viard K, Chaumette MT, et al. Correlations between p53-protein accumulation, serum antibodies and gene mutation in colorectal cancer[J]. Int J Cancer, 1999, 81(5):712-718.
14. Gadducci A, Ferdeghini M, Buttitta F, et al. Assessment of the prognostic relevance of serum anti-p53 antibodies in epithelial ovarian cancer[J]. Gynecol Oncol, 1999, 72(1):76-81.
15. Wong AS, Leung PC. Role of endocrine and growth factors on the ovarian surface epithelium[J]. J Obstet Gynaecol Res, 2007, 33(1):3-16.
16. Callahan MJ, Crum CP, Medeiros F, et al. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction[J]. J Clin Oncol, 2007, 25(25):3985-3990.
17. Kindelberger DW, Lee Y, Miron A, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma:evidence for a causal relationship[J]. Am J Surg Pathol, 2007, 31(2):161-169.
18. Lee Y, Miron A, Drapkin R, et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube[J]. J Pathol, 2007, 211(1):26-35.
19. Levanon K, Crum C, Drapkin R. New insights into the pathogenesis of serous ovarian cancer and its clinical impact[J]. J Clin Oncol, 2008, 26(32):5284-5293.
20. Folkins AK, Jarboe EA, Roh MH, et al. Precursors to pelvic serous carcinoma and their clinical implications[J]. Gynecol Oncol, 2009, 113(3):391-396.

West China Medical Journal

Preliminary Exploration of Correlation between p53 Gene Mutation and Epithelial Ovarian Cancer Pathogenesis Types

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content